Results 121 to 130 of about 4,153 (212)

Finerenone in Diabetic Kidney Disease

Canadian Diabetes & Endocrinology Today
Diabetic kidney disease (DKD) affects 40% of individuals with diabetes mellitus (T2DM) and is associated with an increased risk of cardiovascular events, hospitalization for heart failure, and premature death. Existing treatments focus on lifestyle measures, glycemic control, blood pressure and lipid management, inhibition of the renin‑angiotensin ...
openaire   +1 more source

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes

Diabetology & Metabolic Syndrome
Background Several new treatments have recently been shown to have heart and kidney protective benefits in people with diabetes. Because these treatments were developed in parallel, it is unclear how the different molecular pathways affected by the ...
Duc Tin Tran, Emily S. H. Yeung, Lisa Y. Q. Hong, Harmandeep Kaur, Suzanne L. Advani, Youan Liu, Madiha Zahra Syeda, Sri Nagarjun Batchu, Andrew Advani   +8 more
doaj   +1 more source

Finerenone: pharmacological profile

Klinická farmakologie a farmacie, 2023
openaire   +1 more source

Validation of a De Novo Health Economic Model for Finerenone in Heart Failure with Left Ventricular Ejection Fraction ≥40. [PDF]

J Mark Access Health Policy
Lemański T, Folkerts K, McEwan P, Mernagh P, Żemojdzin MR, Pochopień M.   +5 more
europepmc   +1 more source

Finerenone Utilization for Chronic Kidney Disease and Diabetes: Multicenter Real-World Study in the United States. [PDF]

JACC Adv
Lin W, Schweber A, Xu Y, Chang AR, Farag YM, Mukhopadhyay A, Blecker SB, Horwitz LI, Grams ME, Shin JI.   +9 more
europepmc   +1 more source

Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine - short version [PDF]

, 2017
Anker, Stefan D., Bellou, Abdelouahab, Damman, Kevin, deFilippi, Christopher, Dickstein, Kenneth, Filippatos, Gerasimos, Harjola, Veli-Pekka, Lambrinou, Ekaterini, Laribi, Said, Leite-Moreira, Adelino F., Levy, Phillip, Maggioni, Aldo, Masip, Josep, McDonagh, Theresa, McMurray, John J.V., Mebazaa, Alexandre, Metra, Marco, Mueller, Christian, Peacock, W. Frank, Piepoli, Massimo F., Ponikowski, Piotr, Riley, Jillian P., Ristic, Arsen D., Ruschitzka, Frank, Seferovic, Petar M., Thiele, Holger, Yilmaz, M. Birhan   +26 more
core  

Current Approaches to Treatment and Protein Intake Management in Pre-Dialysis Chronic Kidney Disease: Impact on Physical Exercise [PDF]

Chronic kidney disease (CKD) is the 8th most common condition in the modern world. Unfortunately, it becomes more and more frequent and constitutes a significant global health problem, affecting millions of people worldwide.
Aleksandrowicz, Daria, Głąbień, Marta, Jakubczak, Zofia, Kondratowicz, Aneta, Kusiak, Karolina, Kuśnierz , Anna, Miłkowski, Paweł, Wieczorek, Olga Beata, Zimniak, Maria Weronika, Śliwiak, Patryk   +9 more
core   +1 more source

The appropriateness of finerenone initiation, dosing, and outcomes in diabetic kidney disease: data from real world practice. [PDF]

BMC Nephrol
Sirivongrangson P, Pakdeewongse S, Kumnuch P, Punjachaipornpol T, Srisawat N.   +4 more
europepmc   +1 more source

Inhibition of acalabrutinib metabolism by finerenone and its molecular docking studies. [PDF]

Cell Biol Toxicol
Wang P, Fu H, Wu J, Li R, Cao L, Xu RA, Lin W.   +6 more
europepmc   +1 more source

Efficacy of finerenone in reducing proteinuria in diabetic kidney disease with maximum tolerable doses of dapagliflozin and telmisartan. [PDF]

World J Nephrol
Pasari AS, Gupta S, Gurjar P, Ramteke V, Malde S, Pawar T, Jeyachandran V, Kashiv P, Dubey S, Kurundwadkar M, Sejpal K, Bawankule C, Deshpande N, Balwani MR.   +13 more
europepmc   +1 more source